Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.37 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3284041 | 0.83 | LRRK2 (0.45) | ADORA2AADORA1LRRK2HCAR1HCAR2 | |
| SCHEMBL5065111 | 0.82 | ALDH1A1 (0.51) | ADORA2AADORA1MAPK1MEN1GAA | |
| SCHEMBL330057 | 0.75 | LRRK2 (0.48) | LRRK2MAPTBACE1 | |
| SCHEMBL331551 | 0.75 | TRPV4 (0.47) | ADORA2AADORA1MAPK1MEN1GAA | |
| SCHEMBL330406 | 0.75 | DRD3 (0.45) | ADORA2AADORA1LRRK2MAPK1MEN1 | |
| SCHEMBL330453 | 0.74 | MEN1 (0.46) | MAPK1MEN1MAPTKMT2A | |
| SCHEMBL18113822 | 0.67 | ADORA2A (0.42) | ADORA2AADORA1LRRK2ADORA3ADORA2B | |
| SCHEMBL332076 | 0.67 | TRPV4 (0.41) | LRRK2MEN1MAPTKMT2ANPC1 | |
| SCHEMBL330623 | 0.66 | MEN1 (0.39) | LRRK2MEN1GAAMAPTKMT2A | |
| SCHEMBL330102 | 0.65 | TRPV4 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | ADORA2A 2328/4885ADORA1 2004/4885LRRK2 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.